Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c+CD14+ cells.

Committee on Immunology Univesity of Chicago Chicago IL USA

Deparment of Medicine University of Chicago Chicago IL USA

Department of Dermatology Yale School of Medicine New Haven CT USA

Department of Immunology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Radiation Oncology Weill Cornell Medical College New York NY USA

Sandra and Edward Meyer Cancer Center New York NY USA

Sotio Prague Czech Republic

Université Paris Descartes Paris 5 Paris France

University of Chicago Comprehensive Cancer Center Chicago IL USA

See more in PubMed

Yatim N, Cullen S, Albert ML.. Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017;17:262–2. doi:10.1038/nri.2017.9. PubMed DOI

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10. doi:10.1126/scitranslmed.aao4496. PubMed DOI

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. doi:10.1038/nri.2016.107. PubMed DOI

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. doi:10.1038/nm1523. PubMed DOI

Chen X, Fosco D, Kline DE, Kline J. Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia. Oncoimmunology. 2017;6:e1278332. doi:10.1080/2162402X.2016.1278332. PubMed DOI PMC

Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood. 2016;128:3113–3124. doi:10.1182/blood-2016-08-731737. PubMed DOI PMC

Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010;1:e104. doi:10.1038/cddis.2010.82. PubMed DOI PMC

Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671–688. doi:10.1038/s41577-018-0061-z. PubMed DOI

Husak Z, Dworzak MN. CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity. Cell Death Dis. 2012;3:e425. doi:10.1038/cddis.2012.164. PubMed DOI PMC

Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P, et al. Calreticulin exposure on malignant blasts correlates with improved NK cell-mediated cytotoxicity in AML patients. Haematologica. 2019; In press. PubMed PMC

Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008;8:362–371. doi:10.1038/nri2297. PubMed DOI

Castillo EF, Stonier SW, Frasca L, Schluns KS. Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J Immunol. 2009;183:4948–4956. doi:10.4049/jimmunol.0900719. PubMed DOI PMC

Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32:135–154. doi:10.1016/j.ccell.2017.06.009. PubMed DOI

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients

Calreticulin and cancer

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients